Trials / Completed
CompletedNCT05745701
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants. The 3 study periods will be conducted consecutively without a break.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07081532 | Oral Tablet |
| DEVICE | Cyclosporine | Oral Solution |
| DRUG | Itraconazole | Oral Capsule |
Timeline
- Start date
- 2023-02-22
- Primary completion
- 2023-05-29
- Completion
- 2023-05-29
- First posted
- 2023-02-27
- Last updated
- 2024-09-23
- Results posted
- 2024-09-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05745701. Inclusion in this directory is not an endorsement.